Here, we selected two inhibitors of CDKs (roscovitine (Rosc) and dinaciclib (Dnal)), which are currently in clinical trials for cancer treatment, due to their high specificity for Cdk5 and low inhibitory concentration31, and we evaluated their ability to modulate Drosha expression in TBI models (Fig. 5a). The gene discussed is CDK5; the disease is cancer.